Keith Katkin Syndax Pharmaceuticals Inc (SNDX) insider trading activity

Keith Katkin is of Syndax Pharmaceuticals Inc. Currently has a direct ownership of 100,000 shares of SNDX, which is worth approximately $948,000. The most recent transaction as insider was on May 19, 2025, when has been sold 10,000 shares (Common Stock) at a price of $9.11 per share, resulting in proceeds of $91,100. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 100K

11.11% 3M change

53.85% 12M change

Total Value Held $948,000

Keith Katkin Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 19 2025	BUY Open market or private purchase	$91,100 $9.11 p/Share	10,000 Added 9.09%	100,000 Common Stock
Feb 05 2025	BUY Grant, award, or other acquisition	-	25,000 Added 21.74%	90,000 Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	17,000 Added 20.73%	65,000 Common Stock
Feb 02 2023	BUY Grant, award, or other acquisition	-	16,000 Added 25.0%	48,000 Common Stock
Oct 06 2022	SELL Open market or private sale	$774,384 $25.9 p/Share	29,899 Reduced 48.3%	32,000 Common Stock
Oct 06 2022	BUY Exercise of conversion of derivative security	$251,451 $8.41 p/Share	29,899 Added 42.1%	41,117 Common Stock
Oct 04 2022	SELL Open market or private sale	$9,000 $25.0 p/Share	360 Reduced 1.11%	32,000 Common Stock
Oct 04 2022	BUY Exercise of conversion of derivative security	$3,028 $8.41 p/Share	360 Added 1.1%	32,223 Common Stock
Oct 03 2022	SELL Open market or private sale	$4,500 $25.0 p/Share	180 Reduced 0.56%	32,000 Common Stock
Oct 03 2022	BUY Exercise of conversion of derivative security	$1,514 $8.41 p/Share	180 Added 0.56%	32,013 Common Stock
Sep 30 2022	SELL Open market or private sale	$89,274 $25.07 p/Share	3,561 Reduced 10.01%	32,000 Common Stock
Sep 30 2022	BUY Exercise of conversion of derivative security	$29,948 $8.41 p/Share	3,561 Added 9.83%	32,647 Common Stock
Feb 02 2022	BUY Grant, award, or other acquisition	-	16,000 Added 33.33%	32,000 Common Stock
Feb 03 2021	BUY Grant, award, or other acquisition	-	16,000 Added 50.0%	16,000 Common Stock

Also insider at

RIGL

RIGEL PHARMACEUTICALS INC Healthcare

Director

ELDN

Eledon Pharmaceuticals, Inc. Healthcare

EBS

Emergent BioSolutions Inc. Healthcare

Director

Keith Katkin

Gaithersburg, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SNDX shares.

Notify only if

Value

Insider Trading

Get notified when an Syndax Pharmaceuticals Inc insider buys or sells SNDX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Syndax Pharmaceuticals Inc

Track Activities on SNDX

Account